The reemergence of serious group A streptococcal infections and acute rheumatic fever

American Journal of the Medical Sciences

Volumn 311, Issue 1, 1996, Pages 41-54

  Bronze, Michael S ^b   Dale, James B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Acute rheumatic fever; Group A streptococcal vaccines; Group A streptococci; Streptococcal toxic shock syndrome

Indexed keywords

M PROTEIN; RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE;

ARTICLE; CLINICAL EXAMINATION; HISTORY; HUMAN; NONHUMAN; PATHOGENESIS; PHARYNGITIS; RHEUMATIC FEVER; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME; VACCINATION;

EID: 0030065508     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199601000-00008     Document Type: Article

References (92)

1. Veasy V, Wiedmeier SE, Orsmond GS, Ruttenberg HD, Boucek MM, Roth SJ, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med. 1987;316:421-7.
2. Wald ER, Dashefsky B, Feidt C, Chiponis D, Byers C. Acute rheumatic fever in western Pensylvania and the tristate area. Pediatrics. 1987;80:371-4.
3. Congeni B, Rizzo C, Congeni J, Sreenivasan VV. Outbreak of acute rheumatic fever in northeast Ohio. J Pediatr. 1987;111: 176-9.
4. Hefelfinger DC. Resurgence of acute rheumatic fever in west Alabama. Sooth Med J. 1992;85:761-5.
5. Hosier DM, Craenen JM, Teske DW, Wheller JJ. Resurg ence of acute rheumatic fever. American Journal of Diseases of Children. 1987;141:730-3.
6. Wallace MR, Garst PD, Papadimos TJ, Oldfield EC III, The return of acute rheumatic fever in young adults. JAMA. 1989;262:2557-61.
7. Mason T, Fisher M, Kujala G. Acute rheumatic fever in west Virginia. Arch Intern Med. 1991;151:133-6.
8. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321;1-7.
9. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1989;317:146-9.
10. Demers B, Simor AE, Vellend H, Schlievert PM, Byrne S, Jamieson F, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis. 1963;16:792-800.
11. Bartter T, Dascal A, Carroll K, Curley FJ. Toxic strep syndrome. Arch Intern Med. 1988;148:1421-4.
12. Davies HD, Matlow A, Scriver SR, Schlievert P, Lovgren M, Talbot JA, et al. Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis. 1994;13:49-56.
13. Chapnick EK, Gradon JD, Lutwick LI, Kim J, Levi M, Kim M, et al. Streptococcal toxic shock syndrome due to non-invasive pharyngitis. Clin Infect Dis. 1992;14:1074-7.
14. Leggiadro RJ, Bungnitz MC, Peck BA, Luedtke GS, Kim M, Kaplan EL, et al. Group A streptococcal bacteremia in a mid-south children's hospital. South Med J. 1993;86:615-8.
15. Rathmore MH, Barton LL, Kaplan EL. Suppurative group A β-hemolytic streptococcal infections in children. Pediatrics. 1992;89:743-6.
16. Wheeler MC, Roe MH, Kaplan EL, Schlievert PM, Todd JK. Outbreak of group A streptococcus septicemia in children. JAMA. 1991;266:533-7.
17. Bucher A, Martin PR, Hoiby EA, Halstensen A, Odegaard A, Helium KB, et al. Spectrum of disease in bacteraemic patients during a Streptococcus pyogenes serotype M-1 epidemic in Norway in 1988. Eur J Clin Microbiol Infect Dis. May 1992;11: 416-26.
18. Auerbach SB, Schwartz B, Williams D, Fiorilli MG, Adimora AA, Breiman RF, et al. Outbreak of invasive group A streptococcal infections in a nursing home. Arch Intern Med. 1992;152:1017-22.
19. Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr. 1991;118:341-6.
20. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of 1 streptococcal toxic shock-like syndrome. JAMA. 1993;269:384-9.
21. CDC. Invasive group A streptococcal infections - United Kingdom, 1994. MMWR. 1994;43:401-2.
22. CDC. Group A beta-hemolytic streptocccal bacteremia - Colorado. MMWR. 1990;39:3-6.
23. Lancefield RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962;89:307-13.
24. Beachey EH, Ofek I. Epithelial cell binding of group A streptococci by lipoteichoic acid on fimbriae denuded of M protein. J Exp Med. 1976;143:759-71.
25. Wessels MR, Bronze MS. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci USA. 1994;91:12238-42.
26. Nadal D, Lauener RP, Bragger CP, Kaufhold A, Simma B, Luttickenz R, et al. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr. 1993;122: 727-9.
27. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: Synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis. 1992;165:879-85.
28. Bisno AL. Nonsuppurative poststreptococcal sequelae: Rheumatic fever and glomerulonephritis. In: Mandell GL, Douglas RG, and Bennett JE; eds. Priniciples and Practice of Infectious Diseases, 3rd ed. New York: Churchill Livingstone; 1990:1799-1810.
29. Public Health Board of Denmark. Reported rheumatic fever incidence in Denmark, 1862-1962. In: DiSciasco G, Taranta; eds. Rheumatic Fever in Children. Am Heart J. 1980;99:635-44.
30. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever. The decline of rheumatic fever. Rev Infect Dis. 1989;11: 928-53.
31. Gordis L. The virtual disappearance of rheumatic fever in the United States: Lessons in the rise and fall of disease. Circulation. 1985;72:1155-62.
32. Land MA, Bisno AL. Acute rheumatic fever: A vanishing disease in suburbia. JAMA. 1983;249:895-8.
33. Markowitz M. The decline of rheumatic fever: Role of medical intervention. J Pediatr. 1985;106:545-50.
34. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. Guidelines for the diagnosis of rheumatic fever. JAMA. 1992;268:2969-73.
35. Ferguson GW, Shultz JM, Bisno AL. Epidemiology of acute rheumatic fever in a multiethnic, multiracial urban community. The Miami-Dade county experience. J Infect Dis. 1991;164:720-5.
36. Bisno AL. Group A streptococcal infections and acute rheumatic fever. N Engl J Med. 1991;325:783-93.
37. Stollerman GH. Rheumatogenic group A streptococci and the return of rheumatic fever. Adv Intern Med. 1990;35:1-25.
38. Kaplan EL, Johnson DR, Cleary PP. Group A streptococcal serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the united states in the mid-1980s. J Infect Dis. 1989;159:101-3.
39. Dale JB, Beachey EH. Epitopes of streptococcal M proteins shared with cardiac myosin. J Exp Med. 1989;169:269-83.
40. Bronze MS, Dale JB. Epitopes of streptococcal M protein that evoke antibodies that crossreact with human brain. J Immunol. 1993;151:2820-8.
41. Baird RW, Bronze, MS, Kraus W, Hill HR, Veasey LG, Dale JB. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. J Immunol. 1991;146:3132-7.
42. Stollerman GH. Variation in group A streptococci and the prevalence of rheumatic fever: A half-century vigil. Ann Intern Med. 1993;118:467-9.
43. Schwartz B, Elliott JA, Butler JC, Simon PA, Jameson BL, Welch GE, et al. Clusters of invasive group A streptococcal in family, hospital, and nursing home settings. Clin Infect Dis. 1992;15:277-84.
44. Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis. 1990;22:421-9.
45. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis. 1992;166:31-7.
46. The Working Group on Streptococcal Infections. Denning the group A Streptococcal toxic shock syndrome. JAMA. 1993;269:390-1.
47. Katz AR, Morens DM. Severe streptococcal infections in historical perspective. Clin Infect Dis. 1992;14:298-307.
48. Cock WH. History of scarlet fever, as it appeared in the island of St. Bartholomew, in the years 1829 and 1830, tending to show that the dandy is merely a modification of the disease. Edinburgh Medical and Surgical Journal. 1832;37:28-64.
49. Johnstone J. Remarks on the angina and scarlet fever of 1778. Memoirs of the Medical Society of London. 1778;3:355-67.
50. McCollum JH. Scarlet fever. In: Osier W, McCrae T; eds. Modern Medicine. Its Theory and Practice. Philadelphia: Lea Brothers; 1907;334-72.
51. Donnally HH, Hubbard SD, Emerson H, Solis-Cohen M, Somerset WL, Sharpe FM, et al. Scarlatina: Morbidity and case-fatality, by locality, sex, age and season. Arch Pediatr. 1915;32:767-9.
52. Brackett AS. Scarlet fever from 1675 to 1954. Connecticut State Medical Journal. 1955;19:410-2.
53. Whitelegge BA. The Milroy lectures on changes of type in epidemic diseases. Lecture II. Diseases of more stable type. BMJ. 1893;1:449-51.
54. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis. 1992;14:2-13.
55. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet. 1990;336:1167-71.
56. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, et al. Toxic shock syndrome in menstruating women: Association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980;303:1436-42.
57. Lee PK, Schlievert PM. Quantification and toxicity of group A streptococcal pyrogenic exotoxins in an animal model of toxic shock syndrome-like illness. J Clin Microbiol. 1989;27:1890-2.
58. Talkington DF, Schwartz B, Black CM, Todd JK, Elliott J, Breiman RF, et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun. 1993;61:3369-74.
59. Cleary PP, Kaplan EL, Handley JP, Wlazlo A, Kim MH, Hauser AR, et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet. 1992;339:518-21.
60. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic intections, rheumatic fever or uncomplicated pharyngitis. J Infect Dis. 1992;166:374-82.
61. Caparon MG, Scott JR, Identification of a gene that regulates expression of M protein, the major virulence determinant of group A streptococci. Proc Natl Acad Sci USA. 1987;84:8677-81.
62. Simpson WJ, LaPenta D, Chen C, Cleary PP. Coregulation of type 12 M protein and streptococcal C5a peptidase genes in group A streptococci: Evidence for a virulence regulon controlled by the virR locus. J Bacteriol. 1990;172:690-700.
63. Perez-Casal JF, Dillon HF, Husmann LK, Graham B, Scott JR. Virulence of two Streptococcus pyogenes strains (types M1 and M3) associated with toxic-shock-like syndrome depends on an intact mry-like gene. Infect Immun. 1993;61:5426-30.
64. Spanier JG, Jones SJC, Cleary P. Small DNA deletions creating avirulence in Streptococcus pyogenes. Science. 1984;225: 935-8.
65. Musser JM, Kapur V, Kanjilal S, Shah U, Musher DM, Barg NL, et al. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (scarlet fever toxin). J Infect Dis. 1993;167:337-46.
66. Rotta J, Bednar B. Biological properties of cell wall mucopeptide of hemolytic streptococci. J Exp Med. 1969;130:31-47.
67. Andersen BR, Ducan JL. Inhibition of human lymphocyte blast formation by streptolysin O. J Lab Clin Med. 1874;84:241-8.
68. Ofek I, Bergner-Rabinowitz S, Ginsburg I. Oxygen-stable hemolysis of group A streptococci. VIII. Leukotoxic and antiphagocytic effects of streptolysin S and O. Infect Immun. 1972;6: 459-64.
69. Kim YB, Watson DW. Streptococcal exotoxins: Biological and pathological properties. In Wannamaker LW, Matsen JM; eds. Streptococci and streptococcal diseases. Recognition, understanding and management. New York: Academic Press; 1972;33-50.
70. Dale JB, Simpson W, Ofek I, Beachey EH. Blastogenic responses of human lymphocytes to structurally defined polypeptide fragments of streptococcal M protein. J Immunol. 1981;126: 1499-1505.
71. Tomai M, Kotb M, Majumdar G, Beachey EH. Superantigenicity of streptococcal M protein. J Exp Med. 1990;172:359-62.
72. Michie C, Scott A, Cheesborough J, Beverley P, Pasvol G. Streptococcal toxic shock-like syndrome: Evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin Exp Immunol. 1994;98:140-4.
73. Watanabe-Ohnishi R, Low DE, McGreer A, Stevens DL, Schlievert PM, Newton D, et al. Selective depletion of vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis. 1995;171:74-87.
74. Choi Y, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci USA. 1989;86: 8941-5.
75. Ayoub EM, Barrett DJ, McClaren NK, Krischer JP. As sociation of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest. 1986;77:2019-26.
76. Anastasiou-Nana MI, Anderson JL, Carlquist JR, Nanas JN. HLA-DR typing and lymphocyte subset evaluation in rheumatic heart disease: A search for immune response factors. Am Heart J. 1986;112:992-7.
77. Zabriskie JB, Lavenchy D, Williams RC, Fu SM, Yeadon CA, Fotino M, Braun DG. Rheumatic fever-associated B cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum. 1985;28:1047-51.
78. Denny FW, Wannamalrer LW, Brink WR, Rammelkamp CH, Curter EA. Prevention of rheumatic fever: Treatment of the preceding streptococcal infection. JAMA. 1950;143:151-3.
79. Stollerman GH, Rusoff JH. Prophylaxis against group A streptococcal infections in rheumatic fever patients: Use of new repositiory penicillin preparation. JAMA. 1952;150:1571-5.
80. Lancefield RC. Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med. 1959;110:271.
81. Beachey EH, Campbell GL, Ofek I. Peptic digestion of streptococcal M protein. II. Extraction of M antigen from group A streptococci with pepsin. Infect Immun. 1974;9:891-6.
82. Beachey EH, Stollerman GH, Johnson RH, Ofek I, Bisno AL. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med. 1979;50:862-77.
83. Fischetti VA. Streptococcal M protein: Molecular design and biological behavior. Clin Microbiol Rev. 1989;2:285.
84. Beachey EH, Seyer JM. Protective and nonprotective epitopes of chemically synthesized peptides of the NH2-terminal region of type 6 streptococcal M protein. J Immunol. 1986;136:2287-92.
85. Dale JB, Seyer JM, Beachey EH. Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein. J Exp Med. 1983;58:1727-32.
86. Dale JB, Beachey EH. Localization of protective epitopes of the amino terminus of type 5 streptococcal M protein. J Exp Med. 1986;163:1191-1202.
87. Jones KF, Fischetti VA. The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J Exp Med. 1988;167:1114-23.
88. Cunningham MW, McCormack JM, Fenderson PG, Ho MK, Beachey EH, Dale JB. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J Immunol. 1989;143:2677.
89. Dale JB, Beachey EH. Sequence of myosin-cross-reactive epitopes of streptococcal M protein. J Exp Med. 1986;164:1785-90.
90. Sargent SJ, Beachey EH, Corbett CE, Dale JB. Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranes. J Immunol. 1987;139:1285-90.
91. Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol. 1993;151: 2188.
92. Dale JB, Chiang EC. Intranasal immunization with recombinant group a streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J Infect Dis. 1995;171:1038.